Species distribution and drug susceptibilities of Candida isolates in TSARY 2010

Diagnostic Microbiology and Infectious Disease

Volumn 76, Issue 2, 2013, Pages 182-186

  Yang, Yun Liang ^a   Chen, Hui Ting ^a,b   Lin, Chih Chao ^b   Chu, Wen Li ^b   Lo, Hsiu Jung ^b,c  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Antifungal; Candida species; Drug susceptibility

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ECHINOCANDIN; FLUCONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLASSIFICATION; CROSS RESISTANCE; FUNGUS ISOLATION; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; SPECIES DIFFERENCE; SPECIES DISTRIBUTION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; CANDIDA; DRUG RESISTANCE, MULTIPLE, FUNGAL; ECHINOCANDINS; FLUCONAZOLE; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TAIWAN; TRIAZOLES;

EID: 84877838620     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.03.003     Document Type: Article

References (53)

1. Abi-Said D., Anaissie E., Uzun O., Raad I., Pinzcowski H., Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997, 24:1122-1128.
2. Akova M., Akalin H.E., Uzun O., Gur D. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis 1991, 10:598-599.
3. Alcoba-Florez J., Arevalo Mdel P., Gonzalez-Paredes F.J., Cano J., Guarro J., Perez-Roth E., et al. PCR protocol for specific identification of Candida nivariensis, a recently described pathogenic yeast. J Clin Microbiol 2005, 43:6194-6196.
4. Alcoba-Florez J., Mendez-Alvarez S., Cano J., Guarro J., Perez-Roth E. del Pilar Arevalo M. Phenotypic and molecular characterization of Candida nivariensis sp. nov., a possible new opportunistic fungus. J Clin Microbiol 2005, 43:4107-4111.
5. Almirante B., Rodriguez D., Park B.J., Cuenca-Estrella M., Planes A.M., Almela M., et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005, 43:1829-1835.
6. Arthington-Skaggs B.A., Lee-Yang W., Ciblak M.A., Frade J.P., Brandt M.E., Hajjeh R.A., et al. Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother 2002, 46:2477-2481.
7. Chen P.L., Lo H.J., Wu C.J., Lee H.C., Chang C.M., Lee N.Y., et al. Species distribution and antifungal susceptibility of blood Candida isolates at a tertiary hospital in southern Taiwan, 1999-2006. Mycoses 2011, 54:e17-e23.
8. Chen S., Slavin M., Nguyen Q., Marriott D., Playford E.G., Ellis D., et al. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006, 12:1508-1516.
9. Cheng M.F., Yang Y.L., Yao T.J., Lin C.Y., Liu J.S., Tang R.B., et al. Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species. BMC Infect Dis 2005, 5:22.
10. Cheng M.F., Yu K.W., Tang R.B., Fan Y.H., Yang Y.L., Hsieh K.S., et al. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn Microbiol Infect Dis 2004, 48:33-37.
11. Chou H.H., Lo H.J., Chen K.W., Liao M.H., Li S.Y. Multilocus sequence typing of Candida tropicalis shows clonal cluster enriched in isolates with resistance or trailing growth of fluconazole. Diagn Microbiol Infect Dis 2007, 58:427-433.
12. Chuang Y.C., Chen Y.C., Chang S.C., Sun C.C., Chang Y.Y., Chen M.L., et al. Secular trends of healthcare-associated infections at a teaching hospital in Taiwan, 1981-2007. J Hosp Infect 2010, 76:143-149.
13. Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-third edition, M27-S3 2008, CLSI, Wayne, PA.
14. Colombo A.L., Nucci M., Park B.J., Nouer S.A., Arthington-Skaggs B., da Matta D.A., et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006, 44:2816-2823.
15. Edwards E.J.J. Candida species. In principles and practice of infectious diseases 1995, 2289-2306. Churchill Livingstone Inc, New York. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
16. Fleck R., Dietz A., Hof H. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother 2007, 59:767-771.
17. Hedderwick S.A., Lyons M.J., Liu M., Vazquez J.A., Kauffman C.A. Epidemiology of yeast colonization in the intensive care unit. Eur J Clin Microbiol Infect Dis 2000, 19:663-670.
18. Johnson E. Rare and emerging Candida species. Curr Fungal Infect Rep 2009, 152-159.
19. Kontoyiannis D.P. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis. Clin Infect Dis 2002, 34:1281-1283.
20. Leaw S.N., Chang H.C., Barton R., Bouchara J.P., Chang T.C. Identification of medically important Candida and non-Candida yeast species by an oligonucleotide array. J Clin Microbiol 2007, 45:2220-2229.
21. Lee M.K., Williams L.E., Warnock D.W., Arthington-Skaggs B.A. Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother 2004, 53:217-224.
22. Levin A.S., Costa S.F., Mussi N.S., Basso M., Sinto S.I., Machado C., et al. Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers. Diagn Microbiol Infect Dis 1998, 30:243-249.
23. Li S.Y., Yang Y.L., Lin Y.H., Ko H.C., Wang A.H., Chen K.W., et al. Two closely related fluconazole-resistant Candida tropicalis clones circulating in taiwan from 1999 to 2006. Microb Drug Resist 2009, 15:205-210.
24. Lo H.J., Ho A.H., Ho M. Factors accounting for mis-identification of Candida species. J Microbiol Immunol Infect 2001, 34:171-177.
25. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
26. Peman J., Canton E., Gobernado M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 2005, 24:23-30.
27. Pfaller M.A., Andes D., Arendrup M.C., Diekema D.J., Espinel-Ingroff A., Alexander B.D., et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011, 70:330-343.
28. Pfaller M.A., Andes D., Diekema D.J., Espinel-Ingroff A., Sheehan D. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010, 13:180-195.
29. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20:133-163.
30. Pfaller M.A., Diekema D.J. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010, 36:1-53.
31. Pfaller M.A., Diekema D.J. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012, 50:2846-2856.
32. Pfaller M.A., Diekema D.J., Andes D., Arendrup M.C., Brown S.D., Lockhart S.R., et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011, 14:164-176.
33. Pfaller M.A., Espinel-Ingroff A., Canton E., Castanheira M., Cuenca-Estrella M., Diekema D.J., et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 2012, 50:2040-2046.
34. Pfaller M.A., Jones R.N., Doern G.V., Sader H.S., Messer S.A., Houston A., et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000, 44:747-751.
35. Pfaller M.A., Messer S.A., Boyken L., Tendolkar S., Hollis R.J., Diekema D.J. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004, 42:3142-3146.
36. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N., Doern G.V., Brandt M.E., et al. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis 1999, 33:217-222.
37. Richardson M.D. Opportunistic and pathogenic fungi. J Antimicrob Chemother 1991, 28(Suppl A):1-11.
38. Ruan S.Y., Hsueh P.R. Invasive candidiasis: an overview from Taiwan. J Formos Med Assoc 2009, 108:443-451.
39. Sanglard D., Odds F.C. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002, 2:73-85.
40. Wang J.S., Li S.Y., Yang Y.L., Chou H.H., Lo H.J. Association between fluconazole susceptibility and genetic relatedness among Candida tropicalis isolates in Taiwan. J Med Microbiol 2007, 56:650-653.
41. Warnock D.W. Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi 2007, 48:1-12.
42. White T.C., Marr K.A., Bowden R.A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998, 11:382-402.
43. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317.
44. Yang Y.L., Cheng H.H., Lo H.J. Distribution and antifungal susceptibility of Candida species isolated from different age populations in Taiwan. Med Mycol 2006, 44:237-242.
45. Yang Y.L., Cheng M.F., Wang C.W., Wang A.H., Cheng W.T., Lo H.J., et al. The distribution of species and susceptibility of amphotericin B and fluconazole of yeast pathogens isolated from sterile sites in Taiwan. Med Mycol 2010, 48:328-334.
46. Yang Y.L., Chu W.L., Lin C.C., Tasi S.H., Chang T.C., Lo H.J., et al. An emerging issue of mixed yeast cultures. J Microbiol Immunol Infect 2013, In press.
47. Yang Y.L., Ho Y.A., Cheng H.H., Ho M., Lo H.J. Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Control Hosp Epidemiol 2004, 25:60-64.
48. Yang Y.L., Hsieh L.Y., Wang A.H., Lo H.J. Characterization of Candida Species from Different Populations in Taiwan. Mycopathologia 2011, 172:131-139.
49. Yang Y.L., Li S.Y., Cheng H.H., Lo H.J. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002. Diagn Microbiol Infect Dis 2005, 51:179-183.
50. Yang Y.L., Li S.Y., Cheng H.H., Lo H.J. The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan. BMC Infect Dis 2005, 5:99.
51. Yang Y.L., Lin C.C., Chang T.P., Lauderdale T.L., Chen H.T., Lee C.F., et al. Comparison of human and soil Candida tropicalis isolates with reduced susceptibility to fluconazole. PLoS One 2012, 7:e34609.
52. Yang Y.L., Lo H.J. Mechanisms of antifungal agent resistance. J Microbiol Immunol Infect 2001, 34:79-86.
53. Yang Y.L., Wang A.H., Wang C.W., Cheng W.T., Li S.Y., Lo H.J., et al. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2006. Diagn Microbiol Infect Dis 2008, 61:175-180.